Want to see ACRS full AI Analyst Report?
Top Page
Aclaris Therapeutics
(NASDAQ:ACRS)
Select Model
Select Model
Rating:45Neutral
Price Target:
$3.50
▼(-43.46% Downside)
Action:Reiterated
Date:10/09/26
The score is primarily held down by weak financial performance driven by ongoing losses, declining revenue, and significant negative free cash flow, despite a low-debt balance sheet. Technical indicators also point to a bearish trend (price below major moving averages and negative MACD), with oversold readings providing only limited offset. Valuation is difficult to support with a negative P/E, and the refreshed ATM financing tool adds potential dilution risk.
Positive Factors
Conservative balance sheet
Minimal debt and positive equity give Aclaris a relatively conservative capital structure, reducing fixed repayment pressure while development programs advance. This flexibility can help management allocate cash toward research and partnering opportunities, although it does not eliminate the need to fund ongoing losses.
Negative Factors
Sharp revenue contraction
TTM revenue is only about $8.2M and has contracted sharply, with revenue growth reported at roughly -177% after declines in 2024 and 2025. Sustained top-line deterioration weakens operating leverage, reduces internally generated funding, and makes progress toward a self-financing business less visible.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Minimal debt and positive equity give Aclaris a relatively conservative capital structure, reducing fixed repayment pressure while development programs advance. This flexibility can help management allocate cash toward research and partnering opportunities, although it does not eliminate the need to fund ongoing losses.
Read all positive factors
Aclaris Therapeutics (ACRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$529.92M
Dividend YieldN/A
Average Volume (3M)3.44M
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth-51.05%
EPS Growth57.25%
CountryUS
Employees71
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding147,198,900
10 Day Avg. Volume5,147,075
30 Day Avg. Volume3,442,934
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue80.96
Enterprise Value/Gross Profit84.67
Enterprise Value/Ebitda-8.83
Forecast
1Y Price Target
$12.00Price Target Upside93.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$5.86M
Aclaris Therapeutics Business Overview & Revenue Model
Company Description
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations ...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Aclaris Therapeutics has historically generated revenue primarily through collaboration and licensing-related arrangements (e.g., upfront payments, milestone payments, reimbursement for research and d...
Aclaris Therapeutics Earnings Call Summary
Earnings Call Date:May 07, 2024
(Q1-2024)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Neutral
The earnings call highlights Aclaris' strong financial position and promising advancement of ATI-2138, despite some challenges in cash reserves and competitive landscape considerations. The company is making strategic moves in its drug development with a focus on efficiency and differentiation.Positive Updates
Strong Financial Position
Aclaris ended the first quarter with $161 million in cash, cash equivalents, and marketable securities, with no outstanding debt. This positions the company well financially for upcoming initiatives.
Negative Updates
Decreased Cash Reserves
Cash reserves decreased from $182 million at year-end to $161 million at the end of Q1, partly due to nonrecurring payments related to discontinued programs and severance.
Read all updates
Q1-2024 Updates
Positive
Negative
Strong Financial Position
Aclaris ended the first quarter with $161 million in cash, cash equivalents, and marketable securities, with no outstanding debt. This positions the company well financially for upcoming initiatives.
Read all positive updates
Company Guidance
During the Aclaris Therapeutics Q1 2024 earnings call, several key metrics and strategic updates were provided. The company ended the first quarter with cash, cash equivalents, and marketable securities totaling $161 million, down from $182 million at the end of the previous year. Approximately $14 million of the expenditures in the first quarter were related to nonrecurring payments. Aclaris has decided to advance ATI-2138, their oral small molecule ITK JAK3 inhibitor, into a Phase II proof-of-concept study targeting atopic dermatitis. The study is designed as an open-label trial involving 15 patients over 12 weeks, with a focus on safety, pharmacokinetics (PK), and early efficacy signals. Joseph Monahan highlighted that ATI-2138 is 44.4 times more potent than ritlecitinib in blocking ITK-dependent cytokine production and 5.4 times more potent in JAK3-dependent readouts. Financially, Aclaris is committed to maintaining a strong balance sheet with ongoing cost containment initiatives and exploring business development opportunities to source nondilutive capital.Aclaris Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.22M | 7.83M | 18.72M | 31.25M | 29.75M | 6.76M |
| Gross Profit | 7.86M | 5.74M | 15.93M | 13.17M | 17.79M | 2.05M |
| EBITDA | -75.32M | -64.47M | -51.72M | -115.45M | -84.36M | -64.46M |
| Net Income | -75.74M | -64.92M | -132.06M | -88.48M | -86.91M | -90.86M |
Balance Sheet | ||||||
| Total Assets | 179.69M | 160.46M | 220.33M | 197.41M | 254.60M | 251.21M |
| Cash, Cash Equivalents and Short-Term Investments | 91.56M | 90.75M | 113.59M | 119.11M | 217.57M | 191.41M |
| Total Debt | 0.00 | 2.12M | 0.00 | 426.00K | 684.00K | 693.00K |
| Total Liabilities | 55.11M | 57.38M | 64.77M | 40.23M | 56.98M | 53.87M |
| Stockholders Equity | 124.58M | 103.08M | 155.55M | 157.18M | 197.62M | 197.34M |
Cash Flow | ||||||
| Free Cash Flow | -62.18M | -47.11M | -20.20M | -79.63M | -68.17M | -52.44M |
| Operating Cash Flow | -62.06M | -47.11M | -20.07M | -78.33M | -67.57M | -52.13M |
| Investing Cash Flow | 3.53M | 48.37M | -69.77M | 46.22M | 12.63M | -167.63M |
| Financing Cash Flow | 52.29M | -5.86M | 74.54M | 26.71M | 72.87M | 225.05M |
Aclaris Therapeutics Technical Analysis
Negative
6.19
Price Trends
5.49
Negative
5.24
Negative
4.47
Negative
Market Momentum
-0.57
Positive
28.25
Positive
20.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRS, the sentiment is Negative. The current price of 6.19 is above the 20-day moving average (MA) of 4.71, above the 50-day MA of 5.49, and above the 200-day MA of 4.47, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 28.25 is Positive, neither overbought nor oversold. The STOCH value of 20.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACRS.
Aclaris Therapeutics Risk Analysis
Aclaris Therapeutics disclosed 72 risk factors in its most recent earnings report. Aclaris Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aclaris Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $911.76M | 2.67 | 96.49% | ― | 3.31% | 221.64% | |
70 Outperform | $704.02M | 117.25 | 2.61% | ― | -2.36% | -80.69% | |
58 Neutral | $1.42B | 9.88 | -109.40% | ― | ― | ― | |
54 Neutral | $390.29M | -8.64 | 21.48% | ― | ― | 33.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.23B | -3.84 | -159.32% | ― | ― | 2.95% | |
45 Neutral | $529.92M | -5.98 | -61.65% | ― | -51.05% | 57.25% |
* Healthcare Sector Average
ACRS
Aclaris Therapeutics
3.47
1.66
91.71%
OMER
Omeros
18.88
14.78
360.49%
RIGL
Rigel
47.14
19.76
72.17%
GALT
Galectin Therapeutics
3.69
-1.27
-25.60%
MDXG
MiMedx Group
4.69
-1.89
-28.72%
REPL
Replimune Group
12.11
7.76
178.39%
Aclaris Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Aclaris Updates At-The-Market Equity Sales Agreement
Positive
Aug 6, 2026
On August 6, 2026, Aclaris Therapeutics, Inc., a biopharmaceutical company focused on dermatology and immuno-inflammatory therapies, updated its equity financing arrangements by entering into a Second Amended and Restated Sales Agreement with Leer...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.